Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Orqis Medical: Lake Forest, Calif.-based firm will use proceeds from a $22.7 mil. Series D financing to finish the firm's pivotal, 200-patient, multi-site MOMENTUM trial evaluating Cancion CRS therapy. Orqis says Cancion is the first therapy for congestive heart failure based on continuous aortic blood flow augmentation to the descending aorta (1"The Gray Sheet" Oct. 11, 2004, p. 26). The firm expects to file a PMA in the second half of 2006 for an acute decompensation heart failure indication. Financing proceeds will also support pre-clinical work for Orqis' Exeleras CRS therapy, designed as a long-term implantable therapeutic recovery solution for patients suffering from chronic heart failure. Human trials are several years away, the firm says. New investors Boston Scientific and Lighthouse Capital Partners participated in the financing; other investors included Domain Associates, Johnson & Johnson Development Corporation and HealthCare Ventures...
You may also be interested in...
CircuLite Aims To Transform HF Treatment With Miniature Blood Pump
CircuLite, a New Jersey start-up, aims to begin a U.S. clinical trial next year for a new treatment option for chronic heart failure patients
CircuLite Aims To Transform HF Treatment With Miniature Blood Pump
CircuLite, a New Jersey start-up, aims to begin a U.S. clinical trial next year for a new treatment option for chronic heart failure patients
Endologix financing
Firm inks a $20 mil. private equity placement agreement to support sales force expansion. The extra capitol will enable the company to increase its sales force to 40-50 reps by year-end. The financing builds upon a $15.5 mil. private placement from 2005, which helped the firm launch the PowerLink endoluminal stent graft for treating abdominal aortic aneurysms (1"The Gray Sheet" Aug. 8, 2005, p. 20)...